Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.6420
-0.0452-6.58%
Post-market: 0.66990.0279+4.35%19:59 EDT
Volume:1.49M
Turnover:972.77K
Market Cap:119.48M
PE:-1.11
High:0.6900
Open:0.6673
Low:0.6340
Close:0.6872
Loading ...

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Zacks
·
14 Mar

Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6

MT Newswires Live
·
14 Mar

Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
14 Mar

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

Zacks
·
14 Mar

Q4 2024 Nektar Therapeutics Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
13 Mar

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com
·
13 Mar

Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
11 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

PR Newswire
·
06 Mar

Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
04 Mar

Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
28 Feb

Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Aa Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Severe-to-Very Severe Alopecia Areata

THOMSON REUTERS
·
26 Feb

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

PR Newswire
·
26 Feb

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes

TIPRANKS
·
25 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fresenius Medical Care (FMS), Herbalife (HLF) and Nektar Therapeutics (NKTR)

TIPRANKS
·
25 Feb

William Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
25 Feb

BRIEF-Nektar Announces Clinical Trial Agreement To Evaluate Rezpegaldesleukin

Reuters
·
24 Feb